
|Videos|November 16, 2017
Updates in the Treatment of Relapsed/Refractory Multiple Myeloma
Author(s)Natalie S. Callander, MD
Natalie S. Callander, MD, Professor of Medicine, University of Wisconsin Carbone Cancer Center, discusses updates in the treatment of relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
4
How a Virtual Behavioral Health Program Is Reaching Patients With Cancer Who Need It Most
5










































